- Sanofi (SNY -1.5%) is postponing the conversion of Kiadis Pharma, which it just acquired in April for €308M ($363.6M), to complete statutory buy-out proceedings.
- With the acquisition, Sanofi gained access to Kiadis' "off the shelf" natural killer ("NK") cell technology platform for cancer therapy development.